These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 33191195)

  • 1. Chronic kidney disease and statin eligibility.
    Vega GL; Wang J; Grundy SM
    J Clin Lipidol; 2021; 15(1):173-180. PubMed ID: 33191195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of Coronary Artery Calcium Testing Among Statin Candidates According to American College of Cardiology/American Heart Association Cholesterol Management Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis).
    Nasir K; Bittencourt MS; Blaha MJ; Blankstein R; Agatson AS; Rivera JJ; Miedema MD; Sibley CT; Shaw LJ; Blumenthal RS; Budoff MJ; Krumholz HM
    J Am Coll Cardiol; 2015 Oct; 66(15):1657-68. PubMed ID: 26449135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines.
    Yeboah J; Polonsky TS; Young R; McClelland RL; Delaney JC; Dawood F; Blaha MJ; Miedema MD; Sibley CT; Carr JJ; Burke GL; Goff DC; Psaty BM; Greenland P; Herrington DM
    Circulation; 2015 Sep; 132(10):916-22. PubMed ID: 26224808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in Statin Use Among US Adults With Chronic Kidney Disease, 1999-2014.
    Mefford MT; Rosenson RS; Deng L; Tanner RM; Bittner V; Safford MM; Coll B; Mues KE; Monda KL; Muntner P
    J Am Heart Assoc; 2019 Jan; 8(2):e010640. PubMed ID: 30651020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contrasting Cholesterol Management Guidelines for Adults with CKD.
    Colantonio LD; Baber U; Banach M; Tanner RM; Warnock DG; Gutiérrez OM; Safford MM; Wanner C; Howard G; Muntner P
    J Am Soc Nephrol; 2015 May; 26(5):1173-80. PubMed ID: 25395432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of the 2019 American College of Cardiology/American Heart Association Primary Prevention Guidelines and potential value of the coronary artery calcium score among South Asians in the US: The Mediators of Atherosclerosis in South Asians Living in America (MASALA) study.
    Haque W; Grandhi GR; Kanaya AM; Kandula NR; Nasir K; Al Rifai M; Uddin SMI; Fedeli U; Sattar N; Blumenthal RS; Blaha MJ; Cainzos-Achirica M
    Atherosclerosis; 2021 Oct; 334():48-56. PubMed ID: 34481175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controversies Regarding Lipid Management and Statin Use for Cardiovascular Risk Reduction in Patients With CKD.
    Markossian T; Burge N; Ling B; Schneider J; Pacold I; Bansal V; Leehey D; Stroupe K; Chang A; Kramer H
    Am J Kidney Dis; 2016 Jun; 67(6):965-77. PubMed ID: 26943983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines.
    Steen DL; Khan I; Ansell D; Sanchez RJ; Ray KK
    BMJ Open; 2017 Feb; 7(2):e013255. PubMed ID: 28213597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.
    Pandya A; Sy S; Cho S; Weinstein MC; Gaziano TA
    JAMA; 2015 Jul; 314(2):142-50. PubMed ID: 26172894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum Low-Density Lipoprotein Cholesterol and Cardiovascular Disease Risk Across Chronic Kidney Disease Stages (Data from 1.9 Million United States Veterans).
    Hashemi L; Hsiung JT; Arif Y; Soohoo M; Jackson N; Gosmanova EO; Budoff M; Kovesdy CP; Kalantar-Zadeh K; Streja E
    Am J Cardiol; 2022 May; 170():47-55. PubMed ID: 35300833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low statin use in nondialysis-dependent chronic kidney disease in the absence of clinical atherosclerotic cardiovascular disease or diabetes.
    Markossian TW; Kramer HJ; Burge NJ; Pacold IV; Leehey DJ; Huo Z; Schneider J; Ling B; Stroupe KT
    Clin Kidney J; 2019 Aug; 12(4):530-537. PubMed ID: 31384445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between intensity of statin therapy and mortality in persons with chronic kidney disease.
    Walther CP; Richardson PA; Virani SS; Winkelmayer WC; Navaneethan SD
    Nephrol Dial Transplant; 2020 Feb; 35(2):312-319. PubMed ID: 30053252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012.
    Wong ND; Young D; Zhao Y; Nguyen H; Caballes J; Khan I; Sanchez RJ
    J Clin Lipidol; 2016; 10(5):1109-18. PubMed ID: 27678427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and significance of risk enhancing biomarkers in the United States population at intermediate risk for atherosclerotic disease.
    Vega GL; Wang J; Grundy SM
    J Clin Lipidol; 2022; 16(1):66-74. PubMed ID: 34922882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atherosclerotic Cardiovascular Disease Risk Estimates Using the Predicting Risk of Cardiovascular Disease Events Equations.
    Anderson TS; Wilson LM; Sussman JB
    JAMA Intern Med; 2024 Jun; ():. PubMed ID: 38856978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing potential population impact of statin treatment for primary prevention of atherosclerotic cardiovascular diseases in the USA: population-based modelling study.
    Yang Q; Zhong Y; Gillespie C; Merritt R; Bowman B; George MG; Flanders WD
    BMJ Open; 2017 Jan; 7(1):e011684. PubMed ID: 28119384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statins, Mortality, and Major Adverse Cardiovascular Events Among US Veterans With Chronic Kidney Disease.
    Barayev O; Hawley CE; Wellman H; Gerlovin H; Hsu W; Paik JM; Mandel EI; Liu CK; Djoussé L; Gaziano JM; Gagnon DR; Orkaby AR
    JAMA Netw Open; 2023 Dec; 6(12):e2346373. PubMed ID: 38055276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of the new American College of Cardiology/American Heart Association cholesterol guidelines for primary atherosclerotic cardiovascular disease event prevention in a multi ethnic cohort: Multi-Ethnic Study of Atherosclerosis (MESA).
    Yeboah J; Sillau S; Delaney JC; Blaha MJ; Michos ED; Young R; Qureshi WT; McClelland R; Burke GL; Psaty BM; Herrington DM
    Am Heart J; 2015 Mar; 169(3):387-395.e3. PubMed ID: 25728729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atherosclerotic Cardiovascular Disease Events in Adults With CKD Taking a Moderate- or High-Intensity Statin: The Chronic Renal Insufficiency Cohort (CRIC) Study.
    Poudel B; Rosenson RS; Bittner V; Gutiérrez OM; Anderson AH; Woodward M; Deo R; Carson AP; Mues KE; Dluzniewski PJ; Jaar BG; Lora CM; Taliercio J; Muntner P; Colantonio LD;
    Kidney Med; 2021; 3(5):722-731.e1. PubMed ID: 34693254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.